p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer
Open Access
- 15 January 2006
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (2) , 424-431
- https://doi.org/10.1158/1078-0432.ccr-05-1807
Abstract
Background: The HER-2 receptor undergoes a proteolytic cleavage generating an NH2-terminally truncated fragment, p95HER-2, that is membrane-associated and tyrosine-phosphorylated. We have reported that p95HER-2, but not the full-length receptor, p185HER-2, correlated with the extent of lymph node involvement in patients with breast cancer and its expression was significantly enhanced in nodal metastatic tissue. These facts suggested an important role for p95HER-2 either as a marker or cause of metastasis and poor outcome in breast cancer. In this work, we have studied the prognostic value of p95HER-2 in breast cancer.Keywords
This publication has 33 references indexed in Scilit:
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016Oncogene, 2004
- Tyrosine kinase receptors as attractive targets of cancer therapyCritical Reviews in Oncology/Hematology, 2003
- Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2Oncogene, 2003
- Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs): Simple drugs with a complex mechanism of action?Journal of Cellular Physiology, 2002
- Mechanism of action of trastuzumab and scientific updateSeminars in Oncology, 2001
- The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for TherapyThe International Journal of Cell Cloning, 1998
- FISH detection of HER-2/neu oncogene amplification in early onset breast cancerBreast Cancer Research and Treatment, 1996
- The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studiesMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1995
- Insulin and epidermal growth factor stimulate phosphorylation of p185HER-2 in the breast carcinoma cell line, BT474Molecular and Cellular Endocrinology, 1990